Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study

Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line...

Full description

Bibliographic Details
Main Authors: Sandra Huynh, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, Francois Aubin, Brigitte Dreno, Marie Beylot-Barry, Celeste Lebbe, Wendy Lefevre, Julie Delyon
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
anti-PD1
targeted therapy
BRAF inhibitor
MEK inhibitor
melanoma
Online Access:https://www.mdpi.com/2072-6694/12/6/1666

Internet

https://www.mdpi.com/2072-6694/12/6/1666

Similar Items